白藜芦醇对肝癌Bel-7404细胞增殖、凋亡、侵袭影响机制研究

目的观察白藜芦醇对肝癌细胞Bel-7404增殖、凋亡、侵袭影响,并研究其内在分子机制。方法采用MTT法检测白藜芦醇对Bel-7404细胞增殖的影响;流式细胞术检测白藜芦醇对Bel-7404细胞凋亡的影响;Transwell法检测白藜芦醇对Bel-7404细胞侵袭的影响。蛋白免疫印迹实验检测Pro-caspase 3,PARP,MMP-9及VEGF的表达。结果白藜芦醇可以抑制Bel-7404细胞增殖,呈时间和浓度依赖性。白藜芦醇可以诱导Bel-7404细胞凋亡,呈浓度依赖性,与下调Procaspase3和PARP蛋白表达有关。白藜芦醇可以抑制Bel-7404细胞侵袭性,呈浓度依赖性,与下调MMP-9、VEGF蛋白表达有关。结论白藜芦醇可以抑制肝癌Bel-7404细胞增殖、通过剪切Procaspase3,PARP蛋白而诱导凋亡,通过下调MMP-9和VEGF蛋白表达水平而抑制Bel-7404细胞侵袭性。     

干扰LOX基因对喉癌Hep-2细胞增殖、侵袭及放疗敏感性的影响

目的 探讨抑制赖氨酰氧化酶（LOX）基因表达对喉癌Hep-2细胞增殖、侵袭及放疗敏感性的影响。方法 转染LOX干扰质粒的 Hep-2细胞株,RT-PCR 检测 LOX mRNA,Western blot检测喉癌Hep-2细胞中LOX蛋白及细胞增殖侵袭相关蛋白Ki-67、PCNA、MMP-2/9的表达情况;MTT法检测不同剂量射线对Hep-2细胞生存率的影响,流式细胞术（FCM）检测 Hep-2 细胞凋亡。结果 转染 LOX干扰质粒后 Hep-2细胞中,LOX蛋白和 mRNA 的表达水平下调;Western blot结果显示转染组细胞LOX、Ki-67、PCNA、MMP-2/9蛋白表达明显低于阴性对照组和空白对照组;同时不同剂量射线对Hep-2细胞生存率影响呈剂量依赖性,转染组细胞转染后联合放疗细胞凋亡率明显高于空白及阴性对照组。结论 LOX干扰可特异下调LOX表达,抑制细胞增殖侵袭,作用机制可能与Ki-67、PCNA、MMP-2/9蛋白表达下调有关,并且可增强放疗敏感性,为临床提供一个新的靶点,提高喉鳞癌治疗效果。     

靶向沉默SSBP1基因对肝癌HepG2细胞增殖、侵袭转移的影响

目的 观察靶向沉默线粒体单链DNA结合蛋白(SSBP1)基因对肝癌HepG2细胞增殖、侵袭转移的影响.方法 设计并构建靶向SSBP1 基因的特异性siRNA,采用脂质体介导瞬时转染肝癌HepG2细胞,细胞分3组:对照组、空白转染组、转染组.Real time-PCR和Western-blot检测靶向干扰后SSBP1 mRNA和蛋白表达变化.CCK-8法检测细胞增殖.流式细胞仪检测细胞周期、凋亡率及线粒体膜电位.划痕实验及Transwell 侵袭实验检测细胞侵袭转移能力.Western-blot检测增殖、侵袭转移相关基因蛋白表达状况.结果 SSBP1 siRNA能够显著抑制SSBP1 mRNA和蛋白表达.与对照组和空白转染组比较,转染SSBP1 siRNA后HepG2细胞增殖能力、G2期和S期细胞比例、线粒体膜电位明显降低,G1期细胞比例、细胞凋亡率明显升高(P<0.05);同时细胞增殖相关基因PCNA、凋亡抑制基因Bcl-2、转移相关基因MMP-9蛋白表达显著下调,凋亡诱导基因Bax蛋白表达显著上调(P<0.05).结论 靶向沉默SSBP1基因能够通过线粒体途径抑制肝癌HepG2细胞增殖、侵袭转移,并诱导其凋亡.     

甲基莲心碱体外抑制人肝癌细胞增殖和侵袭的作用机制研究

目的探讨甲基莲心碱(neferine,Nef)对人肝癌HepG2和Bel-7402细胞侵袭的影响和作用机制。方法人肝癌HepG2和Bel-7402细胞体外培养,经不同浓度的甲基莲心碱处理后,CCK-8法检测细胞的增殖,Transwell细胞体外侵袭实验观察Nef对细胞侵袭能力的影响;免疫印迹检测Rho相关蛋白的表达。结果 CCK-8结果显示,与对照组比较,甲基莲心碱干预组抑制人肝癌HepG2和Bel-7402细胞增殖,并呈剂量-效应关系(P<0.05);Transwell细胞体外侵袭实验显示,3μmol·L~(-1)甲基莲心碱明显抑制HepG2和Bel-7402细胞的侵袭;免疫印迹结果显示,3μmol·L~(-1)甲基莲心碱作用HepG2和Bel-7402细胞12 h后,RhoA、RhoC和ROCK表达明显降低。结论甲基莲心碱可体外抑制HepG2和Bel-7402细胞的增殖和侵袭,其抑制肝癌细胞的侵袭可能与抑制RhoA、RhoC和ROCK蛋白的表达有关。     

重组人血管内皮抑制素联合顺铂对人骨肉瘤MG-63细胞VEGF基因表达、增殖及侵袭力的影响

目的 观察重组人血管内皮抑制素(rhEndo)联合顺铂对人骨肉瘤MG-63细胞VEGF基因表达、增殖及侵袭力的影响.方法 顺铂、rhEndo、rhEndo联合顺铂分别处理MG-63细胞,采用RT-PCR和Western blot检测细胞VEGF mRNA和蛋白表达量,CCK-8实验检测细胞增殖,流式细胞术检测细胞凋亡,Transwell小室体外迁移实验检测细胞侵袭和迁移能力.结果 rhEndo联合顺铂组对VEGF mRNA和蛋白表达量、细胞增殖、侵袭迁移的抑制作用以及对细胞凋亡的促进作用均显著高于rhEndo、顺铂单药组,差异有统计学意义(P＜0.05).结论 重组人血管内皮抑制素联合顺铂能够在抑制骨肉瘤MG-63细胞VEGF表达、细胞增殖和侵袭力、促进细胞凋亡方面发挥协同作用.     

不同剂量 γ射线照射对肺癌细胞分化、增殖、凋亡以及放疗敏感性的影响

目的探讨不同剂量 γ射线照射对肺癌细胞分化、增殖、凋亡以及放疗敏感性的影响。方法体外培养的人肺癌细胞株 A549采用随机数字表法分为对照组、 2戈瑞( Gy)组、 4 Gy组、 6 Gy组、 8 Gy组、 10 Gy组,以不同剂量的 γ射线照射细胞,以细胞克隆形成实验检测细胞存活情况;以 CKK?8法检测细胞增殖情况,计算细胞的生长抑制率,检测各组的放疗敏感性;以流式细胞技术检测细胞凋亡情况;采用免疫印记( WB)法检测肺组织分化标志物粘蛋白 MUC?1,肺泡 Ⅱ型上皮细胞特异性蛋白标志物 SPC1、SPC2的表达;以 Transwell细胞体外侵袭实验检测细胞的侵袭能力。结果与对照组比较,照射组细胞相对细胞克隆形成、 MUC?1蛋白表达、侵袭能力降低,生长抑制率、凋亡率、 SPC1、SPC2蛋白表达增高且呈剂量依赖性( P＜0.05);照射组细胞的放疗敏感性呈下降趋势,且 6 Gy组、 8 Gy组、 10 Gy组与 2 Gy组相比有统计学意义( P＜0.05)。结论 γ射线照射可抑制人肺癌细胞株 A549增殖、促进其凋亡、促进其分化、减轻其恶性程度且随剂量增加效果增强;但其放疗敏感性随剂量增加呈下降趋势。     

丙泊酚下调miR-93-5p表达对乳腺癌MDA-MB-231细胞增殖、侵袭的影响

摘要：目的:探讨丙泊酚对miR-93-5p以及人乳腺癌细胞MDA-MB-231增殖及侵袭的影响。方法:培养对数期MDA-MB-231细胞,进行细胞毒性试验,筛选最佳丙泊酚处理浓度与时间,实验分为空白对照组（0.1%DMSO培养基）、阳性对照组(30μmol·L-1环磷酰胺)、丙泊酚1,2,5 mg·L-1浓度组。CCK8法检测细胞增殖,细胞划痕及Transwell实验检测细胞迁移侵袭情况,免疫印迹法（Western Blot）检测增殖相关蛋白增殖细胞核抗原（PCNA）、侵袭迁移相关蛋白金属机制蛋白酶2（MMP-2）、金属机制蛋白酶2（MMP-9）蛋白表达情况,定量即时聚合酶链锁反应（qRT-PCR）检测细胞miR-93-5p表达情况。结果:与空白对照组相比,阳性对照组与丙泊酚各浓度组MDA-MB-231细胞增殖抑制率、迁移抑制率显著升高,裸鼠肿瘤体积、侵袭细胞数量及PCNA、MMP-2、MMP-9蛋白表达、miR-93-5p表达显著降低（P<0.05）。与阳性对照组相比,1 mg·L-1和2 mg·L-1丙泊酚组MDA-MB-231细胞裸鼠肿瘤体积、侵袭细胞数量及PCNA、MMP-2、MMP-9蛋白表达、miR-93-5p表达依次升高,增殖抑制率、迁移抑制率依次降低（P<0.05）。结论:丙泊酚可能通过下调miR-93-5p表达,抑制乳腺癌细胞MDA-MB-231增殖、侵袭能力发挥抗肿瘤作用。     

上调miR-320a对注射用核糖核酸Ⅱ诱导的肝癌Bel-7402细胞凋亡和迁移的影响

目的研究上调miR-320a对注射用核糖核酸Ⅱ(BP素)诱导的肝癌Bel-7402细胞凋亡和迁移的影响。方法用定量逆转录-聚合酶链反应(qRT-PCR)检测miR-320a在正常肝细胞与肝癌细胞中的表达差异;将miR-320a mimic转染到Bel-7402细胞中,qRT-PCR法检测miR-320a的表达水平;CCK-8法检测注射用核糖核酸Ⅱ对肝癌细胞增殖的影响;FCM检测细胞周期分布及凋亡变化;Transwell法检测注射用核糖核酸Ⅱ对肝癌细胞迁移和侵袭的影响;Western blot检测细胞周期蛋白D1的表达及凋亡相关蛋白p53、Bax、Bcl-2,迁移相关蛋白MMP-3的表达。结果与正常肝细胞相比,miR-320a的表达水平在肝癌细胞中明显下调。转染miR-320a mimic的Bel-7402细胞命名为Bel-7402-miR-320a,CCK-8结果显示,给予注射用核糖核酸Ⅱ(100、200、300、400、500 mg·L~(-1))后,Bel-7402及Bel-7402-miR-320a细胞的增殖均受到了抑制。在Bel-7402和Bel-7402-miR-320a中,12h半数抑制浓度为250、200 mg·L~(-1),24 h半数抑制浓度为150、120 mg·L~(-1)。FCM检测结果显示,注射用核糖核酸Ⅱ可诱导Bel-7402、Bel-7402-miR-320a细胞周期阻滞在G0/G1期,上调miR-320a后细胞凋亡率明显增加。Transwell结果显示,与Control组和加药组相比,Bel-7402-miR-320a+Ribonucleic acidⅡ组细胞迁移和侵袭明显受到抑制。Western blot结果显示,注射用核糖核酸Ⅱ作用Bel-7402和Bel-7402-miR-320a细胞后,凋亡相关蛋白p53、Bax的表达增加,而Cyclin D1、Bcl-2、MMP-3蛋白的表达下调。结论 miR-320a在肝癌Bel-7402细胞中的表达水平明显低于正常肝细胞。注射用核糖核酸Ⅱ可以通过下调细胞周期蛋白Cyclin D1的表达,将细胞周期阻滞在G0/G1期,激活p53信号通路,下调Bcl-2、上调Bax,破坏Bcl-2/Bax的比例,促进人肝癌Bel-7402细胞的凋亡,并通过抑制MMP-3的表达抑制人肝癌细胞的迁移和侵袭。而过表达miR-320a后,可提高肝癌细胞对注射用核糖核酸Ⅱ的敏感性,增强注射用核糖核酸Ⅱ对肝癌细胞Bel-7402的作用。     

丙戊酸钠诱导人肝癌细胞株Bel-7402凋亡

目的 探讨丙戊酸钠(VPA)对人肝癌Bel-7402细胞增殖抑制和诱导凋亡作用.方法 采用四甲基偶氮唑蓝(MTT)比色法检测细胞生长的抑制作用,流式细胞术检测细胞凋亡率,免疫组化和Western blot印迹方法检测血管内皮生长因子(VEGF)蛋白的表达水平.结果 VPA对Bel-7402细胞的生长抑制作用呈现时间和剂量依赖性;经1、2和4 mmol/L VPA作用细胞72 h后,细胞的凋亡率由处理前的(2.78±0.32)%,上升为(8.79±0.53)%、(18.65±1.02)%和(36.41±1.93)%;VEGF蛋白的表达明显呈浓度依赖性降低(P＜0.05).结论 VPA对Bel-7402细胞有显著的增殖抑制及诱导凋亡作用,其作用机制可能与下调VEGF的表达有关.     

蛇床子素对肝癌Huh7细胞增殖、凋亡及放射敏感性的影响及机制研究

摘要：目的:探讨蛇床子素对人肝癌Huh7细胞增殖、凋亡及放射敏感性的影响,并初步探究其作用机制。方法:采用不同浓度(0,2.5,5,10,20,40μg·ml-1)的蛇床子素干预人肝癌Huh7细胞,噻唑蓝（MTT）法检测蛇床子素对肝癌Huh7细胞增殖的影响,并计算半数抑制浓度(IC50);10μg·ml-1蛇床子素联合不同照射剂量（0,2,4,6,8 Gy）的X射线处理Huh7细胞,MTT检测细胞增殖能力,筛选照射剂量;克隆形成实验检测Huh7细胞放射敏感性变化,分别采用10μg·ml-1蛇床子素、4 GyX射线照射及两者联合干预Huh7细胞,流式细胞术检测Huh7细胞凋亡率,Western Blot检测Huh7细胞中剪切的含半胱氨酸的天冬氨酸蛋白水解酶3（cleaved caspase-3）和剪切的含半胱氨酸的天冬氨酸蛋白水解酶9（cleaved caspase-9）的表达水平。结果:蛇床子素对肝癌Huh7细胞增殖有明显抑制作用,IC50为20.14μg·ml-1;与单纯照射组相比,蛇床子素联合不同剂量X射线照射下均能够明显抑制细胞存活率,筛选出4 Gy剂量用于后续放射实验。与单纯照射组相比,蛇床子素联合照射组Huh7细胞的放射敏感性、Huh7细胞凋亡率、cleaved caspase-3和cleaved caspase-9蛋白表达显著升高（P<0.05）。结论:蛇床子素能够抑制肝癌Huh7细胞增殖,促进细胞凋亡,并增强细胞对放射的敏感性,其作用机制可能与蛇床子素上调cleaved caspase-3和cleaved caspase-9蛋白表达有关。     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.     

Gender-related symptoms and correlates of alcohol dependence among men and women with a lifetime diagnosis of alcohol use disorders

This study explored gender-related symptoms and correlates of alcohol dependence in a crosssectional study of 150 men and 150 women with a lifetime diagnosis of alcohol use disorders (AUD). Participants were recruited in equal numbers from treatment settings, correctional centres and the general community. Standardized measures were used to determine participants' use of substances, history of psychiatric disorders and psychosocial stress, their sensation seeking and family history of substance use and mental health disorders. Multivariate analyses were used to detect patterns of variables associated with gender and the lifetime severity of AUD. Men had a longer history of severe AUD than women. Women had similar levels of alcohol dependence and medical and psychological sequelae as men, despite 6 fewer years of AUD. More women than men had a history of severe psychosocial stress, severe dependence on other substances and antecedent mental health problems, especially mood and anxiety disorders. There were differences in family history of alcohol-related problems approximating same-gender aggregation. The severity of a lifetime AUD was predicted by its earlier age at onset and the occurrence of other disorders, especially anxiety, among both men and women. The limitations in the generalizability of these findings due to sample idiosyncrasies are discussed.     

Biochemical and molecular characterisation of cubozoan protein toxins

Class Cubozoa includes several species of box jellyfish that are harmful to humans. The venoms of box jellyfish are stored and discharged by nematocysts and contain a variety of bioactive proteins that are cytolytic, cytotoxic, inflammatory or lethal. Although cubozoan venoms generally share similar biological activities, the diverse range and severity of effects caused by different species indicate that their venoms vary in protein composition, activity and potency. To date, few individual venom proteins have been thoroughly characterised, however, accumulating evidence suggests that cubozoan jellyfish produce at least one group of homologous bioactive proteins that are labile, basic, haemolytic and similar in molecular mass (42-46 kDa). The novel box jellyfish toxins are also potentially lethal and the cause of cutaneous pain, inflammation and necrosis, similar to that observed in envenomed humans. Secondary structure analysis and remote protein homology predictions suggest that the box jellyfish toxins may act as α-pore-forming toxins. However, more research is required to elucidate their structures and investigate their mechanism(s) of action. The biological, biochemical and molecular characteristics of cubozoan venoms and their bioactive protein components are reviewed, with particular focus on cubozoan cytolysins and the newly emerging family of box jellyfish toxins.     

Dose tolerability of chronically inhaled voriconazole solution in rodents

Invasive pulmonary aspergillosis (IPA) is a fungal disease of the lung associated with high mortality rates in immunosuppressed patients despite treatment. Targeted drug delivery of aqueous voriconazole solutions has been shown in previous studies to produce high tissue and plasma drug concentrations as well as improved survival in a murine model of IPA. In the present study, rats were exposed to 20 min nebulizations of normal saline (control group) or aerosolized aqueous solutions of voriconazole at 15.625 mg (low dose group) or 31.25 mg (high dose group). Peak voriconazole concentrations in rat lung tissue and plasma after 3 days of twice daily dosing in the high dose group were 0.85 ± 0.63 μg/g wet lung weight and 0.58 ± 0.30 μg/mL, with low dose group lung and plasma concentrations of 0.38 ± 0.01 μg/g wet lung weight and 0.09 ± 0.06 μg/mL, respectively. Trough plasma concentrations were low but demonstrated some drug accumulation over 21 days of inhaled voriconazole administered twice daily. Following multiple inhaled doses, statistically significant but clinically irrelevant abnormalities in laboratory values were observed. Histopathology also revealed an increase in the number of alveolar macrophages but without inflammation or ulceration of the airway, interstitial changes, or edema. Inhaled voriconazole was well tolerated in a rat model of drug inhalation.